5,421 Shares in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Purchased by Cornercap Investment Counsel Inc.

Cornercap Investment Counsel Inc. purchased a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 5,421 shares of the company’s stock, valued at approximately $263,000.

Several other large investors have also recently added to or reduced their stakes in the company. Silvercrest Asset Management Group LLC raised its holdings in shares of Amphastar Pharmaceuticals by 35.1% in the first quarter. Silvercrest Asset Management Group LLC now owns 112,428 shares of the company’s stock valued at $4,937,000 after buying an additional 29,182 shares during the last quarter. International Assets Investment Management LLC bought a new stake in shares of Amphastar Pharmaceuticals during the third quarter valued at approximately $11,070,000. Intech Investment Management LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the second quarter valued at approximately $426,000. Granite Investment Partners LLC raised its position in Amphastar Pharmaceuticals by 12.7% in the 2nd quarter. Granite Investment Partners LLC now owns 397,514 shares of the company’s stock worth $15,901,000 after purchasing an additional 44,744 shares during the last quarter. Finally, Los Angeles Capital Management LLC acquired a new position in Amphastar Pharmaceuticals during the 3rd quarter worth $785,000. 65.09% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director Floyd F. Petersen sold 3,000 shares of the stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $46.47, for a total value of $139,410.00. Following the sale, the director now directly owns 75,409 shares in the company, valued at $3,504,256.23. This trade represents a 3.83 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Rong Zhou sold 6,893 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $48.88, for a total transaction of $336,929.84. Following the transaction, the executive vice president now owns 118,388 shares of the company’s stock, valued at approximately $5,786,805.44. This represents a 5.50 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 31,533 shares of company stock worth $1,571,652. Insiders own 27.10% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on AMPH shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. StockNews.com downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Finally, Piper Sandler lowered their price target on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th.

Amphastar Pharmaceuticals Stock Down 1.0 %

NASDAQ:AMPH opened at $44.16 on Tuesday. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals, Inc. has a 12-month low of $36.56 and a 12-month high of $65.92. The stock’s fifty day simple moving average is $48.40 and its 200-day simple moving average is $44.40. The firm has a market capitalization of $2.12 billion, a P/E ratio of 14.72, a P/E/G ratio of 0.89 and a beta of 0.82.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.